Hospital
Clhg-Ruston LLC
Clhg-Ruston LLC was paid $5.52M by Medicaid between Feb 2018 and Dec 2024, across 107 billing codes. Its largest line is 99284, emergency room visit (serious) — 36% of everything it billed.
33Billing provider infoCLHG-RUSTON LLC
RUSTON, LA 71270
RUSTON, LA 71270
33aNPI1962024026assigned 05/12/2020
33bProvider typeGeneral Acute Care Hospital
28Total paid$5.52M
24GClaims140,965
24DCodes billed107
24AFirst – last monthFeb 2018 – Dec 2024
Compared with peers
Next to other General Acute Care Hospital providers in Louisiana
Rank by total paid#48 of 96
Median peer was paid$5.17M
This provider vs. median1.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2018 | 16 | $0.00 | |
| 2020 | 7,777 | $320K | |
| 2021 | 31,088 | $1.13M | |
| 2022 | 39,342 | $1.70M | |
| 2023 | 36,220 | $1.46M | |
| 2024incomplete | 26,522 | $905K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | 36% | 16,927 | 14,721 | $2.00M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 15% | 11,474 | 10,161 | $811K |
| 99285 | Emergency room visit (most serious)Emergency department visit for the evaluation and management, high severity with immediate threat to life | 14% | 4,982 | 4,397 | $746K |
| 11042 | Debridement, subcutaneous tissue (includes epidermis, dermis, and subcutaneous tissue); first 20 sq cm | 7.6% | 2,609 | 1,009 | $420K |
| 70450 | Computed tomography, head or brain; without contrast material | 3.9% | 1,237 | 1,117 | $215K |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | 3.1% | 4,705 | 4,159 | $170K |
| 80307 | Drug test(s), presumptive, any number of drug classes; immunoassay | 1.7% | 2,013 | 1,700 | $94K |
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 1.6% | 1,836 | 1,624 | $90K |
| 80053 | Comprehensive metabolic panel | 1.6% | 12,264 | 10,696 | $90K |
| 74177 | Computed tomography, abdomen and pelvis; with contrast material | 1.6% | 157 | 144 | $88K |
| 71045 | Radiologic examination, chest; single view | 1.5% | 3,724 | 3,322 | $85K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | 1.4% | 6,080 | 2,781 | $80K |
95 more codes
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.2% | 3,290 | $67K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | 1.2% | 1,848 | $65K |
| 85027 | 1.1% | 12,302 | $59K | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 2,856 | $49K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 1,018 | $38K |
| Q9967 | Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | <1% | 563 | $34K |
| 99214 | Doctor's office visit, returning patient (more involved) | <1% | 808 | $32K |
| 96374 | Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance | <1% | 1,536 | $29K |
| 96375 | Therapeutic injection; each additional sequential IV push | <1% | 775 | $26K |
| 84484 | <1% | 2,687 | $20K | |
| 81025 | <1% | 2,304 | $16K | |
| 96361 | Intravenous infusion, hydration; each additional hour | <1% | 726 | $14K |
| 43239 | Esophagogastroduodenoscopy, flexible, transoral; with biopsy, single or multiple | <1% | 40 | $11K |
| 87502 | Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets | <1% | 155 | $9K |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed | <1% | 171 | $9K |
| 74022 | <1% | 138 | $9K | |
| 87491 | Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe | <1% | 317 | $9K |
| 81003 | <1% | 5,704 | $9K | |
| 87661 | Infectious agent detection by nucleic acid; Trichomonas vaginalis, amplified probe | <1% | 314 | $9K |
| 87591 | Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe | <1% | 314 | $9K |
| 83690 | <1% | 1,588 | $8K | |
| 81001 | <1% | 3,021 | $8K | |
| 85025 | Blood count; complete (CBC), automated, and automated differential WBC count | <1% | 1,319 | $6K |
| 76856 | Ultrasound, pelvic (nonobstetric), real time with image documentation; complete | <1% | 60 | $6K |
| J2405 | Injection, ondansetron hydrochloride, per 1 mg | <1% | 5,409 | $5K |
| 66984 | Extracapsular cataract removal with insertion of intraocular lens prosthesis | <1% | 15 | $5K |
| 87426 | Infectious agent antigen detection, SARS-CoV-2 (COVID-19) | <1% | 201 | $5K |
| 87081 | <1% | 675 | $4K | |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 630 | $4K |
| 45378 | Colonoscopy, flexible; diagnostic, including collection of specimen(s) | <1% | 13 | $4K |
| 76805 | Ultrasound, pregnant uterus, real time with image documentation, fetal and maternal evaluation | <1% | 28 | $4K |
| 72100 | <1% | 103 | $4K | |
| 83880 | <1% | 154 | $3K | |
| 82553 | <1% | 480 | $3K | |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 3,859 | $3K |
| 82150 | <1% | 568 | $3K | |
| 87420 | <1% | 186 | $3K | |
| J0696 | Injection, ceftriaxone sodium, per 250 mg | <1% | 447 | $2K |
| 84702 | <1% | 246 | $2K | |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 89 | $2K |
| 82550 | <1% | 587 | $2K | |
| Q0162 | Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen | <1% | 109 | $2K |
| 59025 | Fetal non-stress test | <1% | 44 | $2K |
| 83735 | <1% | 404 | $2K | |
| 87389 | Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies | <1% | 75 | $1K |
| J7030 | Infusion, normal saline solution , 1000 cc | <1% | 352 | $1K |
| 73564 | <1% | 16 | $1K | |
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 13 | $1K |
| 76817 | Ultrasound, pregnant uterus, real time with image documentation, transvaginal | <1% | 15 | $1K |
| 36415 | Collection of venous blood by venipuncture | <1% | 546 | $1K |
| J1100 | Injection, dexamethasone sodium phosphate, 1 mg | <1% | 686 | $1K |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed | <1% | 24 | $1K |
| C9803 | Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | <1% | 4,633 | $1K |
| 88305 | Level IV - Surgical pathology, gross and microscopic examination | <1% | 207 | $938.98 |
| 96365 | Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour | <1% | 13 | $916.75 |
| Q9963 | High osmolar contrast material, 350-399 mg/ml iodine concentration, per ml | <1% | 73 | $882.71 |
| 96360 | Intravenous infusion, hydration; initial, 31 minutes to 1 hour | <1% | 14 | $840.20 |
| 72125 | Computed tomography, cervical spine; without contrast material | <1% | 17 | $822.45 |
| 77067 | Screening mammography, bilateral, including computer-aided detection | <1% | 13 | $641.28 |
| 85379 | <1% | 73 | $626.31 | |
| 80050 | General health panel | <1% | 15 | $546.48 |
| 85610 | <1% | 215 | $533.75 | |
| 73562 | <1% | 19 | $520.96 | |
| 80048 | Basic metabolic panel (calcium, ionized) | <1% | 85 | $488.19 |
| 86850 | <1% | 161 | $456.11 | |
| 86803 | <1% | 39 | $430.96 | |
| 73610 | <1% | 16 | $426.24 | |
| J2270 | Injection, morphine sulfate, up to 10 mg | <1% | 243 | $393.95 |
| 86787 | <1% | 39 | $388.98 | |
| 86762 | <1% | 31 | $319.46 | |
| 86592 | <1% | 78 | $256.19 | |
| 87340 | <1% | 33 | $249.98 | |
| 86900 | <1% | 170 | $221.54 | |
| 86901 | <1% | 168 | $221.54 | |
| J0702 | Injection, betamethasone acetate 3 mg and betamethasone sodium phosphate 3 mg | <1% | 12 | $216.86 |
| 87210 | <1% | 40 | $193.05 | |
| J2930 | Injection, methylprednisolone sodium succinate, up to 125 mg | <1% | 30 | $182.30 |
| J0780 | Injection, prochlorperazine, up to 10 mg | <1% | 31 | $180.16 |
| J1200 | Injection, diphenhydramine hcl, up to 50 mg | <1% | 122 | $145.62 |
| J2704 | Injection, propofol, 10 mg | <1% | 3,416 | $126.51 |
| 82950 | <1% | 31 | $119.71 | |
| 86140 | <1% | 26 | $98.42 | |
| 77063 | Screening digital breast tomosynthesis, bilateral | <1% | 13 | $78.16 |
| J2550 | Injection, promethazine hcl, up to 50 mg | <1% | 41 | $58.19 |
| J2250 | Injection, midazolam hydrochloride, per 1 mg | <1% | 1,445 | $47.12 |
| J3010 | Injection, fentanyl citrate, 0.1 mg | <1% | 1,135 | $40.75 |
| J0690 | Injection, cefazolin sodium, 500 mg | <1% | 104 | $15.66 |
| J1170 | Injection, hydromorphone, up to 4 mg | <1% | 190 | $15.47 |
| J2274 | Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg | 0% | 26 | $0.00 |
| J0171 | Injection, adrenalin, epinephrine, 0.1 mg | 0% | 14 | $0.00 |
| G0463 | Hospital outpatient clinic visit for assessment and management of a patient | 0% | 36 | $0.00 |
| C9399 | Unclassified drugs or biologicals | 0% | 21 | $0.00 |
| 80320 | 0% | 14 | $0.00 | |
| J2175 | Injection, meperidine hydrochloride, per 100 mg | 0% | 14 | $0.00 |
| J3490 | Unclassified drugs | 0% | 13 | $0.00 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialHALL, KATHY (CEO)
| Provider | Location | Paid |
|---|---|---|
| Clhg-Ruston LLC | Ruston, LA | $207K |
| Clhg-Ruston LLC | Ruston, LA | $3K |
Matched on the authorized-official name exactly as entered in NPPES. A common name can match unrelated people.